vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i5.794vsp-276Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESОПЫТ ПРИМЕНЕНИЯ ПРЕПАРАТА ИНТЕРФЕРОНА β-1А В ЛЕЧЕНИИ РАССЕЯННОГО СКЛЕРОЗА У ДЕТЕЙEХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDRENКузенковаЛ. М.KuzenkovaL. M.

Kuzenkova Lyudmila Mikhaylovna, Doctor of Medical Sciences, Professor, Head of the Department of Psychoneurology and Psychosomatic Pathology SCCH RAMS, Associate Professor of the Pediatrics Department with Pediatric Rheumatology Course at the Faculty of Pediatrics at I.M. Sechenov First Moscow State Medical University

kuzenkova@nczd.ruПакЛ. А.PakL. A.kuzenkova@nczd.ruСтуденикинВ. М.StudenikinV.M.kuzenkova@nczd.ruШатиловаН. Н.ShatilovaN. N.kuzenkova@nczd.ruБурсаговаБ. И.BursagovaB. I.kuzenkova@nczd.ruСмирновИ. Е.SmirnovaI. E.kuzenkova@nczd.ruНаучный центр здоровья детей РАМН, Москва; Первый Московский медицинский государственный университет им. И.М. СеченоваРоссияScientific Centre of Children Health of RAMS, Moscow; I.M. Sechenov First Moscow Medical State UniversityRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health of RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияScientific Centre of Children Health of RAMS, Moscow; N.I. Pirogov Russian National Research Medical University, MoscowRussian Federation201319092013125Вопросы современной педиатрии2429Copyright © Кузенкова Л.М., Пак Л.А., Студеникин В.М., Шатилова Н.Н., Бурсагова Б.И., Смирнов И.Е., 20132013Кузенкова Л.М., Пак Л.А., Студеникин В.М., Шатилова Н.Н., Бурсагова Б.И., Смирнов И.Е.Kuzenkova L.M., Pak L.A., Studenikin V., Shatilova N.N., Bursagova B.I., Smirnova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/276

Aim: to evaluate the impact of subcutaneous interferon β-1a on matrix metalloproteinases 3, 8, 9 (MMP), cytokines (tumor necrosis factor α — TNF α, and transforming growth factor β1 — TGF β1) levels in serum of children with relapsing-remitting multiple sclerosis. Patients and methods: the results of treatment of 32 patients with relapsing-remitting multiple sclerosis aged 12–18 years (22 girls and 10 boys) were analyzed. Treatment efficacy was assessed by the number of relapsing-remitting multiple sclerosis exacerbations during 12 months, MRI data, MMP and cytokines dynamics in serum. Results: statistical evidence acquired for MMPs, their tissue inhibitor and cytokines levels decrease (p < 0,005) in patients receiving therapy with subcutaneous INF β-1a. Conclusions: subcutaneous interferon β-1а is highly efficient in treatment of relapsing-remitting multiple sclerosis in children and adolescents.

детирассеянный склерозматриксные металлопротеиназыцитокиныинтерфероныβ-1аchildrenmultiple sclerosismatrix metalloproteinasescytokinesinterferon β-1aReferencesBoyko A. N., Stolyarov I. D., Sidorenko T. V., Kulakova O. V., Kolyak E. V., Petrov A. M., Ilves A. G., Nikiforova I. G., Favorova O. O., Gusev E. I. Patogeneticheskoe Lechenie Rasseyannogo Skleroza: Nastoyashchee i Budushchee [Pathogenetic Treatment of Multiple Sclerosis: Present and Future]. Zhurnal nevrologii i psikhiatrii [Journal of Neurology and Psychiatry]. 2009; 109 (7, Issue 2): 90–99.Boyko A. N., Stolyarov I. D., Sidorenko T. V., Kulakova O. V., Kolyak E. V., Petrov A. M., Ilves A. G., Nikiforova I. G., Favorova O. O., Gusev E. I. Patogeneticheskoe Lechenie Rasseyannogo Skleroza: Nastoyashchee i Budushchee [Pathogenetic Treatment of Multiple Sclerosis: Present and Future]. Zhurnal nevrologii i psikhiatrii [Journal of Neurology and Psychiatry]. 2009; 109 (7, Issue 2): 90–99.Schmidt T. E., Yakhno N. N. Rasseyannyy Skleroz [Multiple Sclerosis]. Moscow, Meditsina Publ., 2003. 160 p.Schmidt T. E., Yakhno N. N. Rasseyannyy Skleroz [Multiple Sclerosis]. Moscow, Meditsina Publ., 2003. 160 p.Chaudhary A. K., Singh M., Bharti A. C., Asotra K., Sundaram S., Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J. Biomed. Sci. 2010; 17: 10. Doi: 10.1186/1423-0127-17-10.Chaudhary A. K., Singh M., Bharti A. C., Asotra K., Sundaram S., Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J. Biomed. Sci. 2010; 17: 10. Doi: 10.1186/1423-0127-17-10.Lopatinskaya L., Zwemmer J., Uitdehaag B., Lucas K., Polman C., Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult. Scler. 2006; 12 (6): 704–709.Lopatinskaya L., Zwemmer J., Uitdehaag B., Lucas K., Polman C., Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult. Scler. 2006; 12 (6): 704–709.Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 2006; 108 (2): 124–128.Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 2006; 108 (2): 124–128.Candelario-Jalil E., Yang Y., Rosenberg G. A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009; 158 (3): 983–984.Candelario-Jalil E., Yang Y., Rosenberg G. A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009; 158 (3): 983–984.Mazzini F., Nuti E., Petri A., Rossello A. Immobilization of matrix metalloproteinase 8 (MMP-8) for online drug screening. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2011; 879 (11–12): 756–762.Mazzini F., Nuti E., Petri A., Rossello A. Immobilization of matrix metalloproteinase 8 (MMP-8) for online drug screening. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2011; 879 (11–12): 756–762.Shatilova N. N. Dinamika Aktivnosti Matriksnykh Metalloproteinaz i Markerov Apoptoza pri Rasseyannom Skleroze u Detey [Activity Dynamics of Matrix Metalloproteinases and Apoptosis Markers at Multiple Sclerosis in Children]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. М. 2013. 24 p.Shatilova N. N. Dinamika Aktivnosti Matriksnykh Metalloproteinaz i Markerov Apoptoza pri Rasseyannom Skleroze u Detey [Activity Dynamics of Matrix Metalloproteinases and Apoptosis Markers at Multiple Sclerosis in Children]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. М. 2013. 24 p.Boyko A. N., Lashch N.Yu., Slanova A. V., Siluyanova V. A., Kulakova O. G., Favorova O. O. Monitoring Urovnya Matriksnoy Metalloproteinazy 9 (MMP-9) v Otsenke Urovnya Patologicheskogo Protsessa u Bol'nykh s Remitiruyushchim Techeniem Rasseyannogo Skleroza [Monitoring the Level of Matrix Metalloproteinase 9 (MMP-9) in the Assessment of the Pathological Process in Patients with Remitting Multiple Sclerosis]. Neyroimmunologiya [Neuroimmunology]. 2004; II (2): 94.Boyko A. N., Lashch N.Yu., Slanova A. V., Siluyanova V. A., Kulakova O. G., Favorova O. O. Monitoring Urovnya Matriksnoy Metalloproteinazy 9 (MMP-9) v Otsenke Urovnya Patologicheskogo Protsessa u Bol'nykh s Remitiruyushchim Techeniem Rasseyannogo Skleroza [Monitoring the Level of Matrix Metalloproteinase 9 (MMP-9) in the Assessment of the Pathological Process in Patients with Remitting Multiple Sclerosis]. Neyroimmunologiya [Neuroimmunology]. 2004; II (2): 94.Bernal F., Elias B., Hartung H. P., Kieseier B. C. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult. Scler. 2009; 15 (6): 721–727.Bernal F., Elias B., Hartung H. P., Kieseier B. C. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult. Scler. 2009; 15 (6): 721–727.Kanesaka T., Mori M., Hattori T., Oki T., Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2006; 77 (2): 185–188.Kanesaka T., Mori M., Hattori T., Oki T., Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2006; 77 (2): 185–188.Comabella M., Rio J., Espejo C., Ruiz de Villa M., Al-Zayat H., Nos C., Deisenhammer F., Baranzini S. E., Nonell L., Lopez C., Julia E., Oksenberg J. R., Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009; 130 (2): 145–150.Comabella M., Rio J., Espejo C., Ruiz de Villa M., Al-Zayat H., Nos C., Deisenhammer F., Baranzini S. E., Nonell L., Lopez C., Julia E., Oksenberg J. R., Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009; 130 (2): 145–150.Javaid M. A., Abdallah M. N., Ahmed A. S., Sheikh Z. Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol. Belg. 2013; Sep. 4. [Epub ahead of print].Javaid M. A., Abdallah M. N., Ahmed A. S., Sheikh Z. Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol. Belg. 2013; Sep. 4. [Epub ahead of print].Yilmaz U., Gucuyener K., Atak A., Aral A., Gurkas E., Demir E., Serdaroglu A. Matrix metalloproteinase-7 and matrix matalloproteinases-9 in pediatric multiple sclerosis. Pediatr. Neurol. 2012; 47 (3): 171–176.Yilmaz U., Gucuyener K., Atak A., Aral A., Gurkas E., Demir E., Serdaroglu A. Matrix metalloproteinase-7 and matrix matalloproteinases-9 in pediatric multiple sclerosis. Pediatr. Neurol. 2012; 47 (3): 171–176.Ostrand-Rosenberg S., Sinha P., Chornoguz O., Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol. Immunother. 2012; 61 (8): 1319–1325.Ostrand-Rosenberg S., Sinha P., Chornoguz O., Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol. Immunother. 2012; 61 (8): 1319–1325.Raine C. S., Bonetti B., Cannella B. Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev. Neurol. (Paris). 1998; 154 (8–9): 577–585.Raine C. S., Bonetti B., Cannella B. Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev. Neurol. (Paris). 1998; 154 (8–9): 577–585.

The authors declare that there are no conflicts of interest present.